- Home
- TEVA vs ULTA Comparison
TEVA vs ULTA Comparison
Compare TEVA & ULTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEVA
- ULTA
- Stock Information
- Founded
- TEVA 1901
- ULTA 1990
- Country
- TEVA Israel
- ULTA United States
- Employees
- TEVA N/A
- ULTA N/A
- Industry
- TEVA Biotechnology: Pharmaceutical Preparations
- ULTA Other Specialty Stores
- Sector
- TEVA Health Care
- ULTA Consumer Discretionary
- Exchange
- TEVA Nasdaq
- ULTA Nasdaq
- Market Cap
- TEVA 21.2B
- ULTA 23.8B
- IPO Year
- TEVA N/A
- ULTA 2007
- Fundamental
- Price
- TEVA $24.78
- ULTA $517.54
- Analyst Decision
- TEVA Strong Buy
- ULTA Buy
- Analyst Count
- TEVA 7
- ULTA 26
- Target Price
- TEVA $25.86
- ULTA $551.74
- AVG Volume (30 Days)
- TEVA 14.1M
- ULTA 485.2K
- Earning Date
- TEVA 11-05-2025
- ULTA 12-04-2025
- Dividend Yield
- TEVA N/A
- ULTA N/A
- EPS Growth
- TEVA N/A
- ULTA 4.67
- EPS
- TEVA 0.62
- ULTA 26.09
- Revenue
- TEVA $16,776,000,000.00
- ULTA $11,654,555,000.00
- Revenue This Year
- TEVA $4.11
- ULTA $9.53
- Revenue Next Year
- TEVA $0.40
- ULTA $4.74
- P/E Ratio
- TEVA $39.23
- ULTA $19.72
- Revenue Growth
- TEVA 0.02
- ULTA 2.94
- 52 Week Low
- TEVA $12.47
- ULTA $309.01
- 52 Week High
- TEVA $26.38
- ULTA $572.23
- Technical
- Relative Strength Index (RSI)
- TEVA 66.17
- ULTA 48.32
- Support Level
- TEVA $24.01
- ULTA $493.00
- Resistance Level
- TEVA $26.38
- ULTA $543.56
- Average True Range (ATR)
- TEVA 0.91
- ULTA 14.45
- MACD
- TEVA -0.08
- ULTA -0.31
- Stochastic Oscillator
- TEVA 55.03
- ULTA 46.22
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
About ULTA Ulta Beauty Inc.
Ulta Beauty is the largest specialized beauty retailer in the US with about 1,500 freestanding stores. The firm offers cosmetics (39% of 2024 sales), fragrances (13%), skin care (23%), and hair care products (19%). It also has salon services, including hair, makeup, skin, and brow, that account for about 4% of its revenue and drive traffic. Outside of the US, Ulta acquired premium beauty retailer Space NK and its 83 stores in the UK and Ireland in 2025, is opening franchised stores in Mexico, and has formed a joint venture to expand into the Middle East. In addition, Ulta collects royalties through its Target partnership (set to end in 2026) and credit card revenue. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.